Beijing InnoCare Pharma Tech Co.

9969 · HKEX

Public Market Listing

9969HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Beijing InnoCare Pharma Tech Co. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(5 total)
5Total Assets
1Approved
3Phase 3 / Filed
1Phase 1–2 / Early
9Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Approved
CD19Monoclonal antibody
Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin Lymphoma
Large B-Cell Lymphoma
Phase 3
TYK2Small molecule
Psoriasis
Phase 3
BCL-2Small molecule
Acute Myeloid LeukemiaMantle Cell LymphomaChronic Lymphocytic Leukemia
Phase 3
TYK2/JAK1Small molecule
Atopic DermatitisPsoriasis
Phase 1/2
Cereblon E3 ubiquitin-ligaseSmall molecule
Multiple Myeloma

Upcoming events

(15 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Soficitinib (ICP-332)Phase 3Atopic Dermatitis
Est. primary completion 2026-11-25 · NCT06775860 · CT.gov ↗
What to watch
2027 (5)
March 2027 (2)
Soficitinib (ICP-332)Phase 2Prurigo Nodularis (PN)
Est. primary completion 2027-03 · NCT07236099 · CT.gov ↗
What to watch
FadeucravacitinibPhase 2Cutaneous Lupus Erythematosus (CLE)
Est. primary completion 2027-03 · NCT07440537 · CT.gov ↗
What to watch
August 2027 (1)
TafasitamabPhase 2Hematologic Malignancies
Est. primary completion 2027-08-29 · NCT06465433 · CT.gov ↗
What to watch
September 2027 (1)
TafasitamabPhase 2Immune Thrombocytopenia
Est. primary completion 2027-09-23 · NCT07104565 · CT.gov ↗
What to watch
December 2027 (1)
MesutoclaxPhase 2Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Est. primary completion 2027-12 · NCT07082686 · CT.gov ↗
What to watch
2028 (5)
July 2028 (1)
ICP-490Phase 1/2Relapsed or Refractory Non-Hodgkin Lymphoma
Est. primary completion 2028-07 · NCT06845241 · CT.gov ↗
What to watch
September 2028 (2)
Soficitinib (ICP-332)Phase 2/3Chronic Spontaneous Urticaria (CSU)
Est. primary completion 2028-09 · NCT07378527 · CT.gov ↗
What to watch
TafasitamabPhase 3DLBCL
Est. primary completion 2028-09 · NCT06521255 · CT.gov ↗
What to watch
October 2028 (1)
MesutoclaxPhase 3Relapsed/Refractory Marginal Zone Lymphoma (MZL)
Est. primary completion 2028-10 · NCT07896590 · CT.gov ↗
What to watch
December 2028 (1)
FadeucravacitinibPhase 2Primary Sjögren's Syndrome
Est. primary completion 2028-12 · NCT07727486 · CT.gov ↗
What to watch
2029 (2)
April 2029 (1)
Soficitinib (ICP-332)Phase 2/3Non Segmental Vitiligo
Est. primary completion 2029-04 · NCT07047612 · CT.gov ↗
What to watch
December 2029 (1)
MesutoclaxPhase 3Acute Myeloblastic Leukemia
Est. primary completion 2029-12 · NCT07925190 · CT.gov ↗
What to watch
2030 (1)
November 2030 (1)
MesutoclaxPhase 2/3Hematologic Malignancies
Est. primary completion 2030-11-25 · NCT06378138 · CT.gov ↗
What to watch
2032 (1)
October 2032 (1)
MesutoclaxPhase 3Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Est. primary completion 2032-10 · NCT07784101 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 July 2026Topline resultICP-488Phase 3 topline: primary endpoint met
InnoCare Pharma · Source ↗
15 July 2026Topline resultSoficitinib (ICP-332)InnoCare reports the registrational Phase III of soficitinib in atopic dermatitis met its primary endpoint
Beijing InnoCare Pharma Tech Co. · Source ↗
19 June 2026ApprovalTafasitamabJapan approval of Minjuvi with lenalidomide for relapsed/refractory DLBCL
JP, MHLW · Source ↗
5 January 2026Topline resultTafasitamabPhase 3 frontMIND of tafasitamab plus lenalidomide and R-CHOP met its primary endpoint
Incyte · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$76M$33M$1.1B—report ↗

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$330M$132M$1.1B—report ↗

InnoCare reported revenue of $330M (RMB 2,375M), up 135.3% YoY, with gross profit margin up 5.7 percentage points to 92%. R&D spend was $132M (RMB 952M), up 16.9% YoY, while cash and equivalents stood at $1,082M. Net income was $88.6M (RMB 644M), marking the company’s first annual profit, and it achieved positive operating cash flow for the first time.

Business highlights included two out-licensing deals, notably a Zenas agreement for orelabrutinib and autoimmune assets with total value exceeding US$2 billion, plus a Prolium agreement. Approvals included tafasitamab for R/R DLBCL, zurletrectinib for NTRK fusion-positive tumors, and orelabrutinib for 1L CLL/SLL with NRDL inclusion. Pipeline progress included completed Phase III enrollment for soficitinib in atopic dermatitis and ICP-488 in psoriasis, first dosing of the VAV1 degrader ICP-538, ongoing Phase I work for ICP-B794, and an IND submission for ICP-B208. Management’s strategic priorities include securing approvals for five to six innovative drugs, advancing three to four products globally, and progressing five to ten differentiated molecules into clinical trials.